3 Takeaways From FDA's Biosimilar Labeling Guidance
The FDA's highly anticipated guidance Thursday about the labeling of biosimilars attempted to strike a balance that distinguishes the copycat products from brand-name counterparts without making them seem like completely different...To view the full article, register now.
Already a subscriber? Click here to view full article